JIANGSU ANBISON
GenericsJIANGSU ANBISON is a generic drug manufacturer focused on Immunology.
JIANGSU ANBISON's Key Drugs
JIANGSU ANBISON's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
JIANGSU ANBISON's Recent FDA Approvals
New NDA/BLA approvals for JIANGSU ANBISON over the last two years — novel drugs only, excluding generics and label supplements.
JIANGSU ANBISON's Therapeutic Areas
JIANGSU ANBISON's approved drugs and pipeline span 1 therapeutic area, led by Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
JIANGSU ANBISON's Top Competitors
JIANGSU ANBISON's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
JIANGSU ANBISON Pipeline Snapshot
Active clinical trials for JIANGSU ANBISON across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2026-06-01
- Latest
- 2026-06-01
- Applications
- 1